← Back to Search

Home ePRO System for Cancer

N/A

Recruiting

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥18

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is testing a new way for cancer patients to report their symptoms from home, using a navigator to help deliver and manage the program. They want to see if it is helpful and how it affects patients' outcomes.

Who is the study for?

This trial is for cancer patients aged 18 or older who are receiving chemotherapy, targeted therapy, or immunotherapy at the participating institution from 2019 to 2026. It's designed to assess a home electronic Patient-Reported Outcomes (ePRO) system.Check my eligibility

What is being tested?

The study evaluates how well a navigator helps cancer patients use an ePRO system at home across different sites. It looks into what makes it easier or harder to implement this system and its effects on patient care and healthcare usage.See study design

What are the potential side effects?

Since this trial focuses on implementing an ePRO reporting tool rather than a medical treatment, traditional side effects like those seen with medications are not applicable.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Service Penetration

Trial Design

1Treatment groups

Experimental Treatment

Group I: Patient GroupExperimental Treatment1 Intervention

7,500 Patients from UAB/MCI

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,590 Previous Clinical Trials

2,273,982 Total Patients Enrolled

University of South AlabamaOTHER

42 Previous Clinical Trials

8,434 Total Patients Enrolled

Media Library

Patient Group Clinical Trial Eligibility Overview. Trial Name: NCT04809740 — N/A

Cancer Research Study Groups: Patient Group

Cancer Clinical Trial 2023: Patient Group Highlights & Side Effects. Trial Name: NCT04809740 — N/A

Patient Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT04809740 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants being accepted for this trial at the present moment?

"Clinicaltrials.gov confirms that this clinical trial is still in need of participants, with the study first being posted on May 4th 2021 and last updated a year later."

Answered by AI

How many individuals are participants in this experiment?

"Affirmative, according to the information on clinicaltrials.gov this trial is still looking for participants. This experiment was initially published on May 4th 2021 and had its last edit made one year later, also in May of 2022. The research team requires 7500 individuals from 1 medical centre to complete the study."

Answered by AI

Recent research and studies

BMC Health Services ResearchJournal

Evaluating the Implementation and Impact of Navigator-supported Remote Symptom Monitoring and Management: A Protocol for a Hybrid Type 2 Clinical Trial

Rocque, Gabrielle B., J. Nicholas Dionne-Odom, Angela M. Stover, Casey L. Daniel, Andres Azuero, Chao-Hui Sylvia Huang, Stacey A. Ingram, et al.. 2022. “Evaluating the Implementation and Impact of Navigator-supported Remote Symptom Monitoring and Management: A Protocol for a Hybrid Type 2 Clinical Trial”. BMC Health Services Research. Springer Science and Business Media LLC. doi:10.1186/s12913-022-07914-6.

clinicaltrials.govStudy

Evaluating the Implementation and Impact of Navigator-delivered ePRO System

Gabrielle Rocque 2021. "Evaluating the Implementation and Impact of Navigator-delivered ePRO System". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04809740.